Extended Data Fig. 2: Rosiglitazone reduces pro-inflammatory cytokine gene expression and increases PPARy target and anti-inflammatory gene expression.
a, b, Relative gene expression of Pparg and its target gene Cd36 (*p = 0.0258, **p = 0.0037), ‘M2-like’ macrophage marker genes (Mrc1, Mgl1, *P = 0.0301,0.0232, **P = 0.0018) (a) and ‘M1-like’ macrophage marker genes (Tnf, Il1b, Infg, iNOS, *P = 0.0152, **P = 0.0065,0.0096) (b) in eWAT ATMs from Chow, HFD, and Rosi mice. c, d, Geometric mean fluorescence intensity (gMFI) of the M2-marker CD206 (P = 0.0043) (c) and the relative gene expression of the M2-marker gene Mgl1 (P < 0.0001), Pparg (P = 0.0008) and its target gene Cd36 (P = 0.0004), and M1-marker genes (Infg, Il1b, *P = 0.0350, **P = 0.0032) (d) in Rosi-treated M1-BMDMs compared to untreated M1-BMDMs. e, gMFI of CD206 (P = 0.0003) and Trem2 (P = 0.0286), and the percentage of Trem2 (P = 0.0286) from Rosi-treated M0 or M2-BMDMs compared to untreated M0- and M2-BMDMs. Statistical data are expressed as mean ± s.e.m., with each data point representing a biologically independent cell replicate, from three independent cohorts (a,b) or representative of one (e) or three (c,d) independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, with one-way ANOVA, followed by Tukey′s multiple comparisons tests (a,b,e) or an unpaired Mann-Whitney U-test with two-tailed distribution (c and d).
